Kamel Laribi

15PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene and molecular therapyPredictive and prognostic markersCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Apr 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Arthur Coste, Nanthara Sritharan, Anne Lok

|Jul 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.

Juliette Penichoux, Pierre Decazes, Cédric Rossi

|Mar 20, 2024
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).

Kamel Laribi, Stéphanie Poulain, Lise Willems

|Dec 09, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.

Louise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas

|Jul 05, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.

Nadia Younan, Carole Soussain, Sylvain Choquet

|Apr 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.

Lionel Adès, Nicolas Duployez, Agnes Guerci-Bresler

Pageof 3

Frequent Collaborators

2 joint publications

Pierre Fenaux

2 joint publications

Pierre Morel

2 joint publications

Damien Roos-Weil

2 joint publications

Eric Durot